AS
Therapeutic Areas
Zealand Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Survodutide (BI 456906) | Obesity | Phase 3 |
| Dapiglutide (ZE-4600) | Obesity | Phase 2 |
| Zegalogue (dasiglucagon) | Congenital Hyperinsulinism | Approved |
| LAPS GLP-1/Glucagon Dual Agonist | Obesity & Metabolic Diseases | Phase 1 |
| LAPS GLP-1/GLP-2 Dual Agonist | Gastrointestinal Diseases | Preclinical |